EUCTR2008-003202-33-IT
Active, not recruiting
Not Applicable
Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002
ISTITUTO CLINICO HUMANITAS0 sitesNovember 17, 2009
DrugsREVLIMID*21CPS 25MG
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- POEMS SYNDROME
- Sponsor
- ISTITUTO CLINICO HUMANITAS
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Age \> 18 years
- •2\.Patients with a diagnosis of POEMS syndrome based on published diagnostic criteria (Appendix B POEMS syndrome Diagnostic Criteria)
- •3\.Patients with at least a moderate impairment due to neuropathy corresponding to an ONLS of 2 or more
- •4\.Patients with a Karnofsky performance status \= 60%
- •5\.Patients with a life\-expectancy \> 6 months.
- •6\.Patients willing and able to comply with the protocol requirements,
- •7\.Patients who have given voluntary written informed consent before any study\-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •8\.Female patient should be either post\-menopausal or surgically sterilised or willing to use two acceptable method of birth control. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal except oral formulations, and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). Combined oral contraceptive pills are not recommended because they carry an increased risk of venous thromboembolism. If a patient is currently using combined oral contraception, switching to another adequate method of contraception should be considered.
- •9\.Male patient should agree to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study.
- •10\.Patients with the following laboratory values within 14 days before day 1 of the Cycle 1:
Exclusion Criteria
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •2\.Pregnant or breast feeding females.
- •3\.Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk.
- •4\.Use of any other concomitant standard/experimental drug or therapy
- •5\.Any prior use of Revlimid
- •6\.Any of the following laboratory abnormalities:
- •Platelets count \< 75 ? 109/L
- •Absolute neutrophils count \<1\.5 ? 109/L
- •Calculated or measured creatinine clearance \<20 mL/minute.
- •7\.Known positive HIV or active infectious hepatitis, type B or C
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Safety and efficacy of lenalidomide for patients with relapsed or refractory adult T cell leukemia/lymphoma post allogeneic hematopoietic stem cell transplantation, multi-institutional prospective observational trialAdult T-cell leukemia-lymphomaJPRN-UMIN000029635Kagoshima University33
Completed
Phase 2
Efficacy and safety of dose-escalating lenalidomide and dexamethasone (Rd) for unfit patients with relapsed or refractory multiple myelomanfit patients with relapsed or refractory multiple myelomaJPRN-UMIN000019917Gifu University Hospital20
Completed
Not Applicable
To investigate the efficacy and safety of lenalidomide and dexamethasone for elderly or frail patients with relapsed/refractory multiple myelomaMultiple MyelomaJPRN-UMIN000008576Iwate Myeloma treatment Study Group53
Active, not recruiting
Phase 1
The purpose of the study is to determine if the drug lenalidomide (Revlimid®) is able to improve anaemia (low red blood count) and reduce the number of blood transfusions that you require because of Myelodysplastic Syndrome (MDS). The other purpose of the study is to evaluate the effect of the study drug (lenalidomide) on the genetic abnormality (changes in the cell characteristics) associated with MDS.Myelodysplastic Syndrome (MDS) associated with a Del (5q) cytogenetic abnormalityMedDRA version: 16.0 Level: LLT Classification code 10067097 Term: 5q minus MDS System Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2004-005101-29-GBKing's College Hospital NHS Foundation Trust44
Active, not recruiting
Phase 1
Pilot safety/tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for Acute Myeloid Leukaemia/high-risk myelodysplastic syndrome with structural abnormalities of chromosome 5 - AML Len5EUCTR2008-004891-28-GBeeds Teaching Hospitals Trust14